Evidence map›Paper›PMID 31853557›Full record

Trial reportPsychopharmacology2020

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.

Neiloufar Family, Emeline L Maillet, Luke T J Williams, Erwin Krediet, Robin L Carhart-Harris, Tim M Williams, Charles D Nichols, Daniel J Goble, Shlomi Raz

Open access · hybridAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 5 pooled it
18.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 5 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  10. Trial
  11. Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Trial
  19. Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Neiloufar FamilyEleusis Benefit Corporation, New York, NY, USA. neiloufar.family@eleusisltd.com.ORCID http://orcid.org/0000-0002-0201-7119
Emeline L MailletEleusis Benefit Corporation, New York, NY, USA.
Luke T J WilliamsEleusis Benefit Corporation, New York, NY, USA.
Erwin KredietEleusis Benefit Corporation, New York, NY, USA.
Robin L Carhart-HarrisImperial College London, London, UK.
Tim M WilliamsBristol University, Bristol, UK.
Charles D NicholsDepartment of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA, USA.
Daniel J GobleSan Diego State University, San Diego, CA, USA.
Shlomi RazEleusis Benefit Corporation, New York, NY, USA.
Imperial College London · GBLouisiana State University Health Sciences Center New Orleans · USOtis (United States) · USSan Diego State University · USUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research has shown that psychedelics, such as lysergic acid diethylamide (LSD), have profound anti-inflammatory properties mediated by 5-HT

objectiveThis study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally repeated administration of 5 μg, 10 μg, and 20 μg LSD in older healthy individuals. In the current paper, we present safety, tolerability, pharmacokinetics, and pharmacodynamic measures that relate to safety, tolerability, and dose response.

methodsThis was a phase 1 double-blind, placebo-controlled, randomized study. Volunteers were randomly assigned to 1 of 4 dose groups (5 μg, 10 μg, 20 μg LSD, and placebo), and received their assigned dose on six occasions (i.e., every 4 days).

resultsForty-eight older healthy volunteers (mean age = 62.9 years) received placebo (n = 12), 5 μg (n = 12), 10 μg (n = 12), or 20 μg (n = 12) LSD. LSD plasma levels were undetectable for the 5 μg group and peak blood plasma levels for the 10 μg and 20 μg groups occurred at 30 min. LSD was well tolerated, and the frequency of adverse events was no higher than for placebo. Assessments of cognition, balance, and proprioception revealed no impairment.

conclusionsOur results suggest safety and tolerability of orally administered 5 μg, 10 μg, and 20 μg LSD every fourth day over a 21-day period and support further clinical development of LSD for the treatment and prevention of Alzheimer's disease (AD).

Indexed as

Administration, OralAgedCognitionCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHallucinogensHealthy VolunteersHumansLysergic Acid DiethylamideMaleMiddle AgedProprioceptionReaction TimeHallucinogensLysergic Acid Diethylamide5-HT2AAlzheimer’sClinical trialCNSImmune systemInflammationNeurodegenerative diseasePsychedelicsSerotonin

Identifiers

PMID31853557
PMCPMC7036065
OpenAlexW2996366481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.